Publications by authors named "Irene Richiardi"
Article Synopsis
- De-escalation strategies, particularly dose spacing (DS), are being explored for treating atopic dermatitis (AD) patients on dupilumab, allowing longer intervals between injections for those stable or experiencing side effects.
- A retrospective cohort study assessed the safety and effectiveness of DS in AD patients aged ≥18, comparing outcomes before and after DS with a control group not undergoing DS.
- Results showed that after implementing DS, the patients maintained stable skin condition and quality of life measures without significant differences when compared to the control group, indicating DS is both effective and safe for managing severe AD.
Background: There are currently limited data on dupilumab drug survival (DS), especially on factors possibly associated with drug discontinuation.
Materials And Methods: The primary endpoint of this study is to evaluate the parameters that may determine drug discontinuation and the predictive factors associated with dupilumab DS. We considered as independent associated factors: childhood onset of disease, gender, age of onset of AD, age of initiation of dupilumab, previous use of cyclosporine, initial mean EASI, atopic family history, and predisposition to allergic conjunctivitis.